Companies: 10,795·Total market cap: $144.5T
Aura Biosciences, Inc.

Aura Biosciences, Inc.

AURANASDAQHealthcare● Active
$6.47
$-0.16(-2.34%)
Market Cap$415680710
P/E Ratio
52W High$9.535
52W Low$4.73

Aura Biosciences, Inc. (AURA) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

aura · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Aura Biosciences, Inc. (AURA) measures how much investors pay for each dollar of the company's trailing earnings. AURA's current PE ratio of N/A is calculated by dividing its stock price of $6.47 by its TTM earnings per share of -$1.67.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-1.67
Based on 3 analysts
EPS (TTM)
-$1.67
TTM · diluted EPS
PEG Ratio
-0.58
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aura Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Aura Biosciences, Inc.
Aura Biosciences, Inc.You
AURA
$416MN/A-$1.67
Altimmune, Inc.
Altimmune, Inc.
ALT
$241MN/A-$1.00
Annexon, Inc.
Annexon, Inc.
ANNX
$613MN/A-$1.33
DBV Technologies S.A.
DBV Technologies S.A.
DBVT
$383MN/A-$1.70
Design Therapeutics, Inc.
Design Therapeutics, Inc.
DSGN
$657MN/A-$1.22
enGene Holdings Inc.
enGene Holdings Inc.
ENGN
$84MN/A-$2.29
Korro Bio, Inc.
Korro Bio, Inc.
KRRO
$107MN/A-$12.48

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.76
2024-12-31
FY2024
$-1.75
2023-12-31
FY2023
$-1.93
2022-12-31
FY2022
$-1.96
2021-12-31
FY2021
$-1.21
2020-12-31
FY2020
$-0.76
2019-12-31
FY2019
$-0.01

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Aura Biosciences, Inc. (AURA) measures how much investors pay for each dollar of the company's trailing earnings. AURA's current PE ratio of N/A is calculated by dividing its stock price of $6.47 by its TTM earnings per share of -$1.67.

PE Ratio = Stock Price ÷ EPS (TTM)
= $6.47 ÷ -$1.67 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

AURA pe ratio · 6 questions

AURA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $6.47 and TTM EPS of -$1.67. Data sourced from Financial Modeling Prep via AURA's SEC 10-K and 10-Q filings.

AURA PE ratioWhat is AURA PE ratioCurrent PE ratio of AURAAURA PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aura Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08